Stocks with high levels of insider buying the past 3 months and good analyst coverage.

Analysts Target

Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield	Industry
388	HK$391.00	1.6%	-9.1%	HK$500.8b	HK$514.06	26.2	4.9%	3.3%	Diversified Financials
9633	HK$42.22	6.2%	-1.8%	HK$472.6b	HK$55.26	25.9	10.9%	2.7%	Food, Beverage & Tobacco
175	HK$18.48	-0.9%	-2.3%	HK$209.1b	HK$28.96	11.2	16.8%	2.7%	Automobiles
9973 New	HK$24.94	-6.8%	n/a	HK$154.2b	HK$39.86	6.8	9.4%	4.0%	Automobiles
6	HK$59.80	2.3%	19.2%	HK$123.7b	HK$66.20	20.4	0.4%	4.7%	Utilities
823	HK$39.22	4.8%	-7.3%	HK$100.7b	HK$45.23	0.7	51.3%	6.5%	Real Estate
1093	HK$8.10	-0.1%	-11.9%	HK$98.3b	HK$11.48	24.5	14.6%	3.6%	Pharmaceuticals & Biotech
9926	HK$88.35	-9.2%	-37.2%	HK$93.8b	HK$172.29	23.0	46.6%	n/a	Pharmaceuticals & Biotech
1177	HK$4.98	-4.0%	-27.8%	HK$93.7b	HK$8.60	32.7	16.9%	2.0%	Pharmaceuticals & Biotech
6862	HK$11.66	6.5%	-16.2%	HK$66.2b	HK$17.65	13.9	9.5%	6.2%	Consumer Services
6181	HK$350.00	-10.5%	-58.9%	HK$66.0b	HK$842.76	11.0	18.3%	7.9%	Consumer Durables
9863	HK$35.14	-6.9%	-41.7%	HK$52.9b	HK$64.83	80.2	38.7%	n/a	Automobiles
1364	HK$21.36	6.5%	-13.0%	HK$50.9b	HK$32.37	14.1	13.8%	2.3%	Consumer Services
960	HK$6.67	9.3%	-33.6%	HK$48.2b	HK$10.24	40.0	33.6%	0%	Real Estate Management and Development
1530	HK$16.15	-10.6%	-48.5%	HK$44.8b	HK$34.79	4.1	-38.2%	1.5%	Pharmaceuticals & Biotech
3939	HK$9.30	-1.1%	30.8%	HK$44.0b	HK$15.74	26.1	46.6%	1.8%	Materials
101	HK$7.57	6.6%	1.5%	HK$39.4b	HK$10.44	21.8	17.2%	6.9%	Real Estate Management and Development
1828	HK$29.32	1.1%	-23.2%	HK$38.1b	HK$43.54	28.8	25.8%	n/a	Insurance
23	HK$13.63	4.4%	10.6%	HK$35.7b	HK$14.26	0.3	25.9%	4.5%	Banks
2096	HK$12.61	4.3%	6.1%	HK$33.7b	HK$17.79	20.8	18.0%	1.7%	Pharmaceuticals & Biotech
1044	HK$24.08	4.0%	3.6%	HK$27.8b	HK$28.53	9.5	2.8%	6.7%	Household
1318	HK$53.15	4.9%	-46.1%	HK$27.1b	HK$99.06	18.7	17.1%	2.2%	Household
2889	HK$140.00	22.0%	n/a	HK$22.3b	HK$266.22	5.2	101.6%	n/a	Automobiles
9606	HK$215.00	-3.8%	-36.0%	HK$21.4b	HK$433.98	9.1	98.3%	n/a	Pharmaceuticals & Biotech

High Insider Buying